Daiichi Sankyo Company has reported results from Phase III study of an oral antiplatelet agent Prasugrel in patients with coronary artery disease in Japan.

The multi-centre, randomised, double-blind Prasugrel for Japanese patients with coronary artery disease undergoing elective PCI (PRASFIT-Elective) study evaluated the efficacy and safety of Prasugrel plus aspirin. Clopidogrel plus aspirin was used as a reference for patients with stable angina and chronic myocardial infarction undergoing elective percutaneous coronary intervention (PCI).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The rate of composite incidence of cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke was 4.1% in the Prasugrel group compared to 6.7% in the clopidogrel sulfate group.

The rate of non-coronary artery bypass graft (CABG) TIMI major, minor or clinically relevant bleeding was 5.4% in the Prasugrel group compared to 6.2% in the clopidogrel group.

There was no incidence of non-CABG TIMI major bleeding noted in the Prasugrel group while the figure was 2.2% in the clopidogrel group. Similar efficacy and safety results to these were observed in the prior PRASFIT-ACS study.

On the basis of results from the PRASFIT-ACS and PRASFIT-Elective studies, Daiichi Sankyo submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for patients with ischemic heart disease undergoing PCI.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A phase III trial of Prasugrel for patients with ischemic cerebrovascular disease is also being carried out in Japan. It is expected to be completed in 2014.